menu
    • menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Olaratumab","moa":"||Platelet-derived growth factor receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Olaratumab","moa":"||Platelet-derived growth factor receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Telix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals for Olaratumab

    Menu

    Olaratumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eli Lilly

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

                            Details : LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 17, 2023

                            Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Telix Pharmaceuticals

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed

                            Telix Pharmaceuticals

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab

                            Details : The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $5.0 million

                            April 10, 2022

                            Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Eli Lilly

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth